Please, please, please change your mind: Yesterday, King Pharmaceuticals lost its fight with Indian generics maker Lupin when a federal appeals court invalidated the patent on Altace. Today, King says it's asking for a rehearing. The court misapplied precedent and relied on factual inaccuracies, the company says.
The high blood pressure remedy was supposed to be safe through October 2008. With sales of $900 million in the 12 months ended June 30, it makes up about one-third of King's revenues--so you can understand the company's consternation. The company had planned to launch a tweaked version of Altace early next year as a sort of trawling net for BP patients tempted to switch to the generic.
- see the release for more info
King bails on Palatin's FSM program. Report
FDA rejects King's Altace. Report